Checkmate Pharmaceuticals
1 Broadway, 14th floor
Cambridge
Massachusetts
02142
United States
Website: http://checkmatepharma.com/
65 articles about Checkmate Pharmaceuticals
-
Regeneron Completes Acquisition of Checkmate Pharmaceuticals
5/31/2022
Acquisition strengthens Regeneron's innovative portfolio of immuno-oncology candidates and diversified approach to cancer treatment.
-
University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
5/26/2022
Checkmate Pharmaceuticals, Inc. announced the University of Iowa Holden Comprehensive Cancer Center’s presentation of preliminary data from an investigator-sponsored phase 1/2 trial evaluating vidutolimod, a first-in-class, immunostimulatory, noninfectious virus-like particle containing a CpG-A Toll-like receptor 9 agonist.
-
Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update
5/12/2022
Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2022 financial results and provided a business update.
-
Despite the loss of its COVID-19 antibody, REGEN-COV, earlier this year, Regeneron posted a positive first quarter driven primarily by sales of Dupixent and Eylea.
-
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types
4/19/2022
Regeneron Pharmaceuticals, Inc. and Checkmate Pharmaceuticals, Inc. a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer, announced a definitive agreement for the acquisition of Checkmate by Regeneron at an all-cash price of $10.50 per share of Checkmate common stock.
-
Regeneron Augments I-O Portfolio with Checkmate, Partners with SpringWorks on Multiple Myeloma
4/19/2022
Regeneron announced it has acquired Checkmate Pharmaceuticals and that it has entered a clinical trial collaboration with SpringWorks Therapeutics to treat multiple myeloma. -
Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business Update
3/29/2022
Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced full year 2021 financial results and provided a business update.
-
Biopharma companies are preparing to unveil new data for various oncology programs at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans next month.
-
Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting
3/8/2022
Checkmate Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced that it will present biomarker data at the 2022 American Association for Cancer Research Annual Meeting taking place in New Orleans, Louisiana from April 8-13, 2022.
-
BioSpace Movers & Shakers, Feb. 11
2/11/2022
Well into the new year, biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers. -
Checkmate Pharmaceuticals Appoints Alan Bash as President and CEO
2/9/2022
Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced the appointment of Alan Bash as President and Chief Executive Officer, effective March 1, 2022.
-
Checkmate Pharmaceuticals Welcomes Industry Leader Jon Wigginton, M.D. to its Board of Directors
1/31/2022
Checkmate Pharmaceuticals, Inc. today announced the addition of Jon Wigginton, M.D. to its Board of Directors (“Board”).
-
Checkmate Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
1/3/2022
Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced that Alan Fuhrman, Interim CEO and President, will present at the H.C. Wainwright BioConnect Virtual Conference being held on January 10-13, 2022.
-
Checkmate Pharmaceuticals Strengthens Board of Directors with Appointment of Joy Yan, M.D., Ph.D. Nilesh Kumar, Ph.D. departs Board of Directors upon transition to new role at Wellington Management
12/20/2021
Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced the addition of Joy Yan, M.D., Ph.D. to its Board of Directors.
-
Checkmate Pharmaceuticals Announces Initiation of Patient Dosing in Phase 2 Multi-Indication Trial Using Vidutolimod
12/20/2021
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), today announced that patient dosing was initiated in the anti-PD-1 refractory cutaneous squamous cell carcinoma (CSCC) arm of a Phase 2 multi-indication study evaluating the efficacy and safety of vidutolimod in combination with cemiplimab for the treatment of patients with anti-PD-1 refractory CSCC.
-
Many big companies, including Amgen, Moderna, Roche and Novartis, had already decided not to attend in-person and the sentiment was leaning that way.
-
Checkmate Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
11/15/2021
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman, Interim CEO and President, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.
-
Checkmate Pharmaceuticals Presents Final Clinical Data for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
11/12/2021
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, today announced the presentation of final clinical data from the Phase 1b study, CMP-001-001 (NCT02680184), of vidutolimod.
-
Checkmate Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
11/12/2021
Checkmate Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced third quarter 2021 financial results and provided a business update.
-
Checkmate Pharmaceuticals to Present at the Jefferies London Healthcare Conference
11/11/2021
Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), today announced that James Wooldridge, MD, Chief Medical Officer, will present virtually at the Jefferies London Healthcare Conference taking place November 16-19, 2021.